• Gilead Sciences to acquire MYR GmbH expresspharma
    December 11, 2020
    Gilead to acquire Hepcludex, a first-in-class entry inhibitor, for treatment of chronic hepatitis delta virus (HDV), after closing of transaction.
PharmaSources Customer Service